

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: A61K 31/47, C07D 315/22, 215/227, 215/233	A1	(11) International Publication Number: WO 94/27605 (43) International Publication Date: 8 December 1994 (08.12.94)
(21) International Application Number: PCT/US94/06145 (22) International Filing Date: 31 May 1994 (31.05.94) (30) Priority Data: 08/069,005 28 May 1993 (28.05.93) US (71) Applicants: STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE, OREGON [US/US]; P.O. Box 3175, Eugene, OR 97403 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, 22nd floor, Oakland, CA 94612-3550 (US). (72) Inventors: CAI, Sui, Xiong; 3900 Parkview Lane #6B, Irvine, CA 92715 (US). KEANA, John, F., W.; 3854 Onyx Street, Eugene, OR 97405 (US). WEBER, Eckard; 1560 Del Mar Avenue, Laguna Beach, CA 92651 (US). (74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein & Fox, Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: 1,2,3,4-TETRAHYDROQUINOLINE-2,3,4-TRIONE-3 OR 4-OXIMES AND USE (57) Abstract <p>Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions and inducing anesthesia are disclosed by administering to an animal in need of such treatment a substituted or unsubstituted 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oxime or pharmaceutically acceptable salts thereof which have high binding to the glycine receptor.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Title of the ⁻¹⁻Invention

"1,2,3,4-TETRAHYDROQUINOLINE-2,3,4-TRIONE-3 OR 4-OXIMES AND USE"

5 The present invention was made with U.S. government support.
Therefore, the U.S. Government has certain rights in the invention.

Field of the Invention

10 The present invention is in the field of medicinal chemistry. In particular, the present invention relates to substituted and unsubstituted 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and pharmaceutically acceptable salts thereof and their use to treat or prevent neuronal degeneration associated with ischemia, pathophysiologic conditions associated with neuronal degeneration, convulsions, anxiety, and chronic pain as well as to induce anesthesia and treat or prevent psychosis.

Background of the Invention

15 Glutamate is thought to be the major excitatory neurotransmitter in the brain. There are three major subtypes of glutamate receptors in the CNS. These are commonly referred to as kainate, AMPA and N-methyl-D-aspartate (NMDA) receptors (Watkins and Olverman, *Trends in Neurosci.* 7:265-272 (1987)). NMDA receptors are found in the membranes of virtually every
20 neuron in the brain. NMDA receptors are ligand-gated cation channels that allow Na⁺, K⁺ and Ca⁺⁺ to permeate when they are activated by glutamate or aspartate (non-selective, endogenous agonists) or by NMDA (a selective, synthetic agonist) (Wong and Kemp, *Ann. Rev. Pharmacol. Toxicol.* 31:401-
25 425 (1991)).

Glutamate alone cannot activate the NMDA receptor. In order to become activated by glutamate, the NMDA receptor channel must first bind

-2-

glycine at a specific, high affinity glycine binding site which is separate from the glutamate/NMDA binding site on the receptor protein (Johnson and Ascher, *Nature* 325:329-331 (1987)). Glycine is therefore an obligatory co-agonist at the NMDA receptor/channel complex (Kemp, J.A., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6547-6550 (1988)).

Besides the binding sites for glutamate/NMDA and glycine, the NMDA receptor carries a number of other functionally important binding sites. These include binding sites for Mg^{++} , Zn^{++} , polyamines, arachidonic acid and phencyclidine (PCP) (Reynolds and Miller, *Adv. in Pharmacol.* 21:101-126 (1990); Miller, B., *et al.*, *Nature* 355:722-725 (1992)). The PCP binding site --now commonly referred to as the PCP receptor--is located inside the pore of the ionophore of the NMDA receptor/channel complex (Wong, E.H.F., *et al.*, *Proc. Natl. Acad. Sci. USA* 83:7104-7108 (1986); Huettner and Bean, *Proc. Natl. Acad. Sci. USA* 85:1307-1311 (1988); MacDonald, J.F., *et al.*, *Neurophysiol.* 58:251-266 (1987)). In order for PCP to gain access to the PCP receptor, the channel must first be opened by glutamate and glycine. In the absence of glutamate and glycine, PCP cannot bind to the PCP receptor although some studies have suggested that a small amount of PCP binding can occur even in the absence of glutamate and glycine (Sircar and Zukin, *Brain Res.* 556:280-284 (1991)). Once PCP binds to the PCP receptor, it blocks ion flux through the open channel. Therefore, PCP is an open channel blocker and a non-competitive glutamate antagonist at the NMDA receptor/channel complex.

One of the most potent and selective drugs that bind to the PCP receptor is the anticonvulsant drug MK-801. This drug has a K_d of approximately 3nM at the PCP receptor (Wong, E.H.F., *et al.*, *Proc. Natl. Acad. Sci. USA* 83:7104-7108 (1986)).

Both PCP and MK-801 as well as other PCP receptor ligands [e.g., dextromethorphan, ketamine and N,N,N'-trisubstituted guanidines] have neuroprotective efficacy both *in vitro* and *in vivo* (Gill, R., *et al.*, *J. Neurosci.* 7:3343-3349 (1987); Keana, J.F.W., *et al.*, *Proc. Natl. Acad. Sci. USA*

86:5631-5635 (1989); Steinberg, G.K., *et al.*, *Neuroscience Lett.* 89: 193-197 (1988); Church, J., *et al.*, In: *Sigma and Phencyclidine-Like Compounds as Molecular Probes in Biology*, Domino and Kamenka, eds., Ann Arbor: NPP Books, pp. 747-756 (1988)). The well-characterized neuroprotective efficacy of these drugs is largely due to their capacity to block excessive Ca^{++} influx into neurons through NMDA receptor channels which become over activated by excessive glutamate release in conditions of brain ischemia (e.g., in stroke, cardiac arrest ischemia etc.) (Collins, R.C., *Metabol. Br. Dis.* 1:231-240 (1986); Collins, R.C., *et al.*, *Annals Int. Med.* 110:992-1000 (1989)).

However, the therapeutic potential of these PCP receptor drugs as ischemia rescue agents in stroke has been severely hampered by the fact that these drugs have strong PCP-like behavioral side effects (psychotomimetic behavioral effects) which appear to be due to the interaction of these drugs with the PCP receptor (Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 167:127-135 (1989); Koek, W., *et al.*, *J. Pharmacol. Exp. Ther.* 245:969 (1989); Willets and Balster, *Neuropharmacology* 27:1249 (1988)). These PCP-like behavioral side effects appear to have caused the withdrawal of MK801 from clinical development as an ischemia rescue agent. Furthermore, these PCP receptor ligands appear to have considerable abuse potential as demonstrated by the abuse liability of PCP itself.

The PCP-like behavioral effects of the PCP receptor ligands can be demonstrated in animal models: PCP and related PCP receptor ligands cause a behavioral excitation (hyperlocomotion) in rodents (Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 167:127-135 (1989)) and a characteristic catalepsy in pigeons (Koek, W., *et al.*, *J. Pharmacol. Exp. Ther.* 245:969 (1989); Willets and Balster, *Neuropharmacology* 27:1249 (1988)); in drug discrimination paradigms, there is a strong correlation between the PCP receptor affinity of these drugs and their potency to induce a PCP-appropriate response behavior (Zukin, S.R., *et al.*, *Brain Res.* 294:174 (1984); Brady, K.T., *et al.*, *Science* 215:178 (1982); Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 141:497 (1987)).

Drugs acting as competitive antagonists at the glutamate binding site of the NMDA receptor such as CGS 19755 and LY274614 also have neuroprotective efficacy because these drugs--like the PCP receptor ligands--can prevent excessive Ca^{++} flux through NMDA receptor/channels in ischemia (Boast, C.A., *et al.*, *Brain Res.* 442:345-348 (1988); Schoepp, D.D., *et al.*, *J. Neural. Trans.* 85:131-143 (1991)). However, competitive NMDA receptor antagonists also have PCP-like behavioral side-effects in animal models (behavioral excitation, activity in PCP drug discrimination tests) although not as potently as MK-801 and PCP (Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 167:127-135 (1989)).

An alternate way of inhibiting NMDA receptor channel activation is by using antagonists at the glycine binding site of the NMDA receptor. Since glycine must bind to the glycine site in order for glutamate to effect channel opening (Johnson and Ascher, *Nature* 325:329-331 (1987); Kemp, J.A., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6547-6550 (1988)), a glycine antagonist can completely prevent ion flux through the NMDA receptor channel--even in the presence of a large amount of glutamate.

Recent *in vivo* microdialysis studies have demonstrated that in the rat focal ischemia model, there is a large increase in glutamate release in the ischemic brain region with *no* significant increase in glycine release (Globus, M.Y.T., *et al.*, *J. Neurochem.* 57:470-478 (1991)). Thus, theoretically, glycine antagonists should be very powerful neuroprotective agents, because they can prevent the opening of NMDA channels by glutamate non-competitively and therefore--unlike competitive NMDA antagonists--do not have to overcome the large concentrations of endogenous glutamate that are released in the ischemic brain region.

Furthermore, because glycine antagonists act at neither the glutamate/-NMDA nor the PCP binding sites to prevent NMDA channel opening, these drugs might not cause the PCP-like behavioral side effect seen with both PCP receptor ligands and competitive NMDA receptor antagonists (Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 167:127-135 (1989); Koek, W., *et al.*, *J.*

Pharmacol. Exp. Ther. 245:969 (1989); Willets and Balster, *Neuropharmacology* 27:1249 (1988); Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 167:127-135 (1989); Zukin, S.R., *et al.*, *Brain Res.* 294:174 (1984); Brady, K.T., *et al.*, *Science* 215:178 (1982); Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 141:497 (1987)). That glycine antagonists may indeed be devoid of PCP-like behavioral side effects has been suggested by recent studies in which available glycine antagonists were injected directly into the brains of rodents without resulting in PCP-like behaviors (Tricklebank, M.D., *et al.*, *Eur. J. Pharmacol.* 167:127-135 (1989)).

However, there have been two major problems which have prevented the development of glycine antagonists as clinically useful neuroprotective agents:


- A. Most available glycine antagonists with relatively high receptor binding affinity *in vitro* such as 7-Cl-kynurenic acid (Kemp, J.A., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6547-6550 (1988)), 5,7-dichlorokynurenic acid (McNamara, D., *et al.*, *Neuroscience Lett.* 120:17-20 (1990)) and indole-2-carboxylic acid (Gray, N.M., *et al.*, *J. Med. Chem.* 34:1283-1292 (1991)) cannot penetrate the blood/brain barrier and therefore have no utility as therapeutic agents;
- B. The only widely available glycine antagonist that sufficiently penetrates the blood/brain barrier--the drug HA-966 (Fletcher and Lodge, *Eur. J. Pharmacol.* 151:161-162 (1988))--is a partial agonist with micromolar affinity for the glycine binding site. A neuroprotective efficacy for HA-966 *in vivo* has not been demonstrated nor has it been demonstrated for the other available glycine antagonists because they lack bioavailability *in vivo*.

-6-

A need continues to exist for potent and selective glycine/NMDA antagonists which can penetrate the blood/brain barrier and which:

- lack the PCP-like behavioral side effects common to the PCP-like NMDA channel blockers such as MK801 or to the competitive NMDA receptor antagonists such as CGS19755;
- show potent anti-ischemic efficacy because of the non-competitive nature of their glutamate antagonism at the NMDA receptor;
- have utility as novel anticonvulsants with fewer side-effects than the PCP-like NMDA channel blockers or the competitive NMDA antagonists;
- help in defining the functional significance of the glycine binding site of the NMDA receptor *in vivo*.

There have been a number of reports in the literature regarding the preparation of 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 and 4-oximes. For example, Fadda, A.A. *et al.*, *Pharmazie* 46:743-4 (1991), disclose compounds having the formula:



These compounds were employed as intermediates for the preparation of benzenesulphonyl derivatives with antibacterial and anticandidal activities. See also, Fadda, A.A. *et al.*, *J. Indian Chem. Soc.* 68:393-5 (1991).

Hardman and Partridge, *J. Chem. Soc.* 614-20 (1958), disclose 7-chloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime. Hardman and Partridge report that most of the quinoline derivatives described in their

-7-

communication were examined for amoebacidal activity, but that no activity was observed.


Masoud, M.S. *et al.*, *Revue Roum. Chim.* 26:961-5 (1991), disclose osmium complexes of 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (5
quinisatin oxime) and their use as an analytical reagent.

Stankevicius, A. *et al.*, *Chem. Abstr.* 112:138465t (1990), disclose 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime and the mass-spectroscopic analysis thereof.

Prisyazhnyuk, P.V. *et al.*, *Chem. Abstr.* 101:171042y (1984), disclose
10 the reaction of 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime with a quinaldinium salt to give a conjugate having activity against gram positive bacteria.

Ayres and Roach, *Anal. Chim. Acta* 26:332-339 (1962), disclose the complexation of 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (quinisatin
15 oxime) with iron (II).

Stankevicius, A. *et al.*, *Chem. Abstr.* 115:114174h (1991), disclose compounds having the formula:




wherein R' is arylsulfonyl and A may be -NHCO- (1,2,3,4-tetrahydro-
20 quinoline-2,3,4-trione-4-oxime). These compounds are reported to be useful as intermediates for the preparation of cyanocarboxylic acid amides.

Summary of the Invention

The invention relates to a method of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery,

-8-

as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, as well as treating anxiety, convulsions, chronic pain, psychosis and inducing anesthesia, comprising administering to an animal in need of such treatment a compound of the Formula (I)



(I)

or a pharmaceutically acceptable salt thereof;


wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocycloxy group, aralkoxy or haloalkoxy.

The present invention resulted from the initial discovery that 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime and 1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime exhibit high binding to the glycine receptor. Since 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 and 4-oxime are highly selective for the glycine receptor, it is expected that the compounds of the present invention may not exhibit the PCP-like behavioral side effects common to the PCP-like NMDA channel blockers such as MK-801 and other NMDA antagonists such as CGS19755. Thus, the compounds of the present invention are useful for treating pathophysiologic conditions, without significant side effects or toxicity.

Description of the Preferred Embodiments

The present invention relates to substituted and unsubstituted 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes which are highly selective, competitive antagonists of the glycine binding site of the NMDA receptor and of the excitatory amino acids. The 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oximes which may be employed in the practice of the invention have the following Formula (II):



(II)

or a pharmaceutically acceptable salt thereof;

wherein


R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocycloxy group, aralkoxy or haloalkoxy.

Of course, it is to be understood that R₁-R₄ may be the same or different. It is also to be understood that the oximes of the present invention exist as syn and/or anti isomers. The present invention is also directed to such isomers and mixtures of such isomers.

The 1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oximes which may be used in the practice of the present invention have the following Formula (III):

-10-



(III)

wherein R and R₁ - R₄ are as defined above.

Preferred compounds within the scope of Formulae II and III are wherein R₁ and R₃ are other than hydrogen, e.g., R₁ is nitro, amino, chloro or bromo; R₂ is hydrogen, chloro, bromo or trifluoromethyl; R₃ is nitro, chloro, bromo or trifluoromethyl; and R₄ is hydrogen, nitro, chloro, bromo or amino.

Typical C₆₋₁₄ aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl groups.

Typical aryloxy groups include any of the C₆₋₁₄ aryl groups linked by oxygen to any of the 5-, 6-, 7- and/or 8- positions of the quinoline ring, e.g. phenoxy and 1-naphthyloxy groups.

Typical substituted aryl groups include any of the C₆₋₁₄ aryl groups substituted by one or more halo, nitro, cyano, alkyl, alkenyl, and alkynyl groups, e.g. 2-chlorophenyl, 2,4-dibromophenyl and the like.

Typical substituted aryloxy groups include any of the C₆₋₁₄ aryl groups substituted by one or more halo, nitro, cyano, alkyl, alkenyl, and alkynyl groups, and linked by oxygen to any of the 5-, 6-, 7- and/or 8- positions of the quinoline ring, e.g. 2-chlorophenoxy, 2,4-dibromophenoxy and the like.

Typical aryloyl groups include any of the above-mentioned aryl groups substituted by a carbonyl group.

Typical heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranal, isobenzofuranyl, chromenyl, xanthenyl, phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indoliziny, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinoliziny, isoquinolyl, quinolyl,

phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β -carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl and phenoxazinyl groups.

5 Typical heteroaryloxy groups include any of the heteroaryl groups linked by oxygen to any of the 5-, 6-, 7- and/or 8- positions of the quinoline ring, e.g. 2-furanoxy, 4-pyridoxy, 2-pyrazinoxy, purine-6-oxy and the like.

 Typical heterocyclic groups include tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, 10 imidazolynyl, indolynyl, isoindolynyl, quinuclidinyl, morpholynyl, isochromanyl, chromanyl, pyrazolidinyl, pyrazolynyl and the like.

 Typical heterocycloxy groups include any of the heterocyclic groups linked by oxygen to any of the 5-, 6-, 7- and/or 8- positions of the quinoline ring, e.g. 4-tetrahydropyranyloxy.

15 Typical amino groups include NH_2 , NHR_5 and NR_5R_6 , wherein R_5 and R_6 are C_{1-4} alkyl groups.

 Typical halo groups include fluorine, chlorine, bromine and iodine.

 Typical C_{1-4} alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec.*-butyl, and *tert.*-butyl groups.

20 Typical C_{2-4} alkenyl groups include vinyl, allyl, 1-butenyl, 2-butenyl, 3-butenyl, and isobutenyl groups.

 Typical C_{2-4} alkynyl groups include propargyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butyne and 3-butyne groups.

25 Typical aralkoxy groups include C_{1-4} alkoxy groups substituted by any one of the aryl groups mentioned above.

 Typical haloalkyl groups include C_{1-4} alkyl groups substituted by one or more fluorine, chlorine, bromine or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl and trichloromethyl groups.

-12-

Typical alkoxy groups include any one of the C₁₋₄ alkyl groups mentioned above linked by oxygen to any of the 5-, 6-, 7- and/or 8- positions of the quinoline ring.

5 Typical haloalkoxy groups include any one of the alkoxy groups substituted by one or more fluoro, chloro, bromo or iodo groups, e.g., trifluoromethoxy, trichloromethoxy, 2-chloroethoxy, 2-bromoethoxy, pentafluoroethyl, 3,3,3-trichloropropoxy, 4,4,4-trichlorobutoxy and the like.

10 Typical trialkylsilyl-substituted alkoxy groups include any one of the C₁₋₄ alkoxy groups substituted by a C₃₋₆ trialkylsilyl group, e.g. 2-trimethylsilylethoxy, 2-triethylsilylethoxy and 2-(*t*-butyldimethylsilyl)ethoxy and the like.

Typical C₂-C₆ acyl groups include acetyl, propionyl, butanoyl and pentanoyl groups.

15 Typical C₂-C₆ acyl groups substituted by halogen include the above-mentioned acyl groups substituted by one or more fluoro, chloro, bromo or iodo groups, e.g., trifluoroacetyl.

Particularly preferred compounds which may be used in the practice of the present invention include, but are not limited to 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5-chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5-chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5-bromo-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5-bromo-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7-dichloro-8-nitro-1,2,3,4-

20

25

30

- tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7-dibromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7-dibromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7-dibromo-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7-dibromo-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7-dichloro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7-dichloro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7-dibromo-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7-dibromo-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7-difluoro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7-difluoro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,7-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,7-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5-(trifluoromethyl)-6-chloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5-(trifluoromethyl)-6-chloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5-(trifluoromethyl)-6-bromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5-(trifluoromethyl)-6-bromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5-(trifluoromethyl)-6-fluoro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5-(trifluoromethyl)-6-fluoro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6-chloro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6-chloro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6-fluoro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6-fluoro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6-chloro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6-chloro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6-bromo-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6-bromo-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6-fluoro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-

trione-3-oxime, 6-fluoro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,7-dichloro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,7-dichloro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,7-dibromo-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,7-dibromo-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,7-difluoro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,7-difluoro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 5,7-bis(trifluoromethyl)-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 5,7-bis(trifluoromethyl)-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 6,7,8-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, 6,7,8-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-oxime, 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5-chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5-chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5-bromo-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5-bromo-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6,7-dibromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7-dibromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6,7-dibromo-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7-dibromo-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-

acetyloxime, 6,7-dichloro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7-dichloro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6,7-dibromo-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7-dibromo-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6,7-difluoro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7-difluoro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,7-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,7-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5-(trifluoromethyl)-6-chloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5-(trifluoromethyl)-6-chloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5-(trifluoromethyl)-6-bromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5-(trifluoromethyl)-6-bromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5-(trifluoromethyl)-6-fluoro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5-(trifluoromethyl)-6-fluoro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6-chloro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6-chloro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6-fluoro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6-fluoro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6-chloro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6-chloro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6-bromo-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6-bromo-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6-fluoro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6-fluoro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,7-dichloro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,7-

- dichloro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,7-dibromo-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,7-dibromo-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,7-difluoro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,7-difluoro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 5,7-bis(trifluoromethyl)-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 5,7-bis(trifluoromethyl)-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 6,7,8-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime, 6,7,8-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-acetyloxime, 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5-chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5-chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5-bromo-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5-bromo-7-trifluoromethyl-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6,7-dichloro-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6,7-dibromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6,7-dibromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6,7-dibromo-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6,7-dibromo-8-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6,7-dichloro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6,7-dichloro-5-nitro-1,2,3,4-

tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6,7-dibromo-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6,7-dibromo-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6,7-difluoro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6,7-difluoro-5-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5,7-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,7-bis(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5-(trifluoromethyl)-6-chloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5-(trifluoromethyl)-6-chloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5-(trifluoromethyl)-6-bromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5-(trifluoromethyl)-6-bromo-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5-(trifluoromethyl)-6-fluoro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5-(trifluoromethyl)-6-fluoro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6-chloro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6-chloro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6-bromo-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6-fluoro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6-fluoro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6-chloro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6-chloro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6-bromo-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6-bromo-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 6-fluoro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 6-fluoro-5-nitro-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5,7-dichloro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,7-dichloro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-

4-benzoyloxime, 5,7-dibromo-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,7-dibromo-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5,7-difluoro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,7-difluoro-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, 5,7-bis(trifluoromethyl)-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime, 5,7-bis(trifluoromethyl)-6-nitro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-4-benzoyloxime, and 6,7,8-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-benzoyloxime.

Certain of the compounds of the present invention are expected to be potent anticonvulsants in animal models and will prevent ischemia-induced nerve cell death in the gerbil global ischemia model after i.p. administration.

The compounds of the present invention are active in treating or preventing neuronal loss, neurodegenerative diseases, chronic pain, are active as anticonvulsants and antipsychotics and for inducing anesthesia. Certain of the compounds of the present invention are expected to exhibit little or no untoward side effects caused by non-selective binding with other receptors, particularly, the PCP and glutamate receptors associated with the NMDA receptor. In addition, certain of the compounds may block kainate, AMPA and quisqualate receptors and are therefore useful as broad-spectrum excitatory amino acid receptor antagonists. Moreover, the compounds of the present invention are effective in treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, e.g., those which are involved in the NMDA receptor system, by blocking the glycine receptors and preventing the ligand-gated cation channels from opening and allowing excessive influx of Ca^{++} into neurons, as occurs during ischemia.

Neurodegenerative diseases which may be treated with the compounds of the present invention include those selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome.

The compounds of the present invention find particular utility in the treatment or prevention of neuronal loss associated with multiple strokes which

give rise to dementia. After a patient has been diagnosed as suffering from a stroke, the compounds of the present invention may be administered to ameliorate the immediate ischemia and prevent further neuronal damage that may occur from recurrent strokes.

5 Moreover, the compounds of the present invention are able to cross the blood/brain barrier which makes them particularly useful for treating or preventing conditions involving the central nervous system.

 The compounds of the invention find particular utility in treating or preventing the adverse neurological consequences of surgery. For example,
10 coronary bypass surgery requires the use of heart-lung machines which tend to introduce air bubbles into the circulatory system which may lodge in the brain. The presence of such air bubbles robs neuronal tissue of oxygen, resulting in anoxia and ischemia. Pre- or post- surgical administration of the 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oximes of the present invention will
15 treat or prevent the resulting ischemia. In a preferred embodiment, the compounds of the invention are administered to patients undergoing cardiopulmonary bypass surgery or carotid endarterectomy surgery.

 The compounds of the present invention also find utility in treating or preventing chronic pain. Such chronic pain may be the result of surgery,
20 trauma, headache, arthritis, or other degenerative disease. The compounds of the present invention also find particular utility in the treatment of phantom pain that results from amputation of an extremity. In addition to treatment of pain, the compounds of the invention are also expected to be useful in inducing anesthesia, either general or local anesthesia, for example, during
25 surgery.

 The glycine and excitatory amino acid antagonists may be tested for *in vivo* anticonvulsant activity after intraperitoneal injection using a number of anticonvulsant tests in mice (audiogenic seizure model in DBA-2 mice, pentylenetetrazol-induced seizures in mice, NMDA-induced death). The
30 compounds may also be tested in drug discrimination tests in rats trained to discriminate PCP from saline. It is expected that most of the compounds of


the present invention will not generalize to PCP at any dose. In addition, it is also expected that none of the compounds will produce a behavioral excitation in locomotor activity tests in the mouse. It is expected that such results will suggest that the glycine, AMPA, kainate and quisqualate antagonists of the present invention do not show the PCP-like behavioral side effects that are common to NMDA channel blockers such as MK-801 and PCP or to competitive NMDA antagonists such as CGS19755.

The glycine and excitatory amino acid antagonists are also expected to show potent activity *in vivo* after intraperitoneal injection suggesting that these compounds can penetrate the blood/brain barrier.

The compounds of the present invention may be tested for potential glycine antagonist activity by observing the inhibition of binding of $1\mu\text{M}$ glycine-stimulated [^3H]-MK-801 in rat or guinea pig brain membrane homogenates. The more potent the glycine antagonist, the less [^3H]-MK-801 can bind since the [^3H]-MK801 binding site (PCP receptor) is accessible only upon opening of the ion channel by glutamate and glycine (Fletcher, E.L., *et al.*, in *Glycine Neurotransmission*, Otterson, P., *et al.* (eds.), John Wiley and Sons (1990); Johnson, J.W., *et al.*, *Nature* 325:529 (1987)).


1,2,3,4-Tetrahydroquinoline-2,3,4-trione-3-oxime *17a* (Dahn, H. and Donzel, A., *Helv. Chim. Acta* 50:1911-1917 (1967)) was prepared by reaction of 2,4-quinolinediol (Aldrich) *15a* with $\text{NaNO}_2/\text{H}_2\text{SO}_4$ (eq.8). ^1H NMR shows that *17a* is a mixture of two stereoisomers *17aa* and *17ab* in a ratio of 0.3:0.7 (the specific isomers were not determined). All the other 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oximes prepared also are mixtures of two isomers. Compound *17a* was found to have a K_i value of $20\mu\text{M}$ with a potency of 1.3% of DCK.

-21-




5,7-Dichloro-2,4-quinolinediol *15b* (the tautomer 5,7-Dichloro-4-hydroxy-1,2-dihydroquinolin-2-one is depicted in the following scheme) was prepared by reaction of 3,5-dichloroaniline with diethyl malonate followed by basic hydrolysis and cyclization in polyphosphoric acid (PPA) (Patel, G.H. and Mehta, C.M., *J. Sci. Industr. Res.* 19B:436-438 (1960)). 5,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime *17b* was prepared from *15b* by reaction with $\text{NaNO}_2/\text{H}_2\text{SO}_4$ (eq. 9). *17b* was found to be highly active as an antagonist for the glycine/NMDA receptor. It has a K_i value of 0.02 μM , which is about 1000 times more active than the unsubstituted compound *17a* and is 1126% of DCK. Similar to *17a*, *17b* also is a mixture of two stereoisomers in a ratio of 0.4:0.6.

-22-




A mixture of about 1:1 of 6,7-dichloro-2,4-quinolinediol *15c* and 5,6-dichloro-2,4-quinolinediol *15d* were obtained by reaction of 3,4-dichloroaniline with diethyl malonate under similar conditions as that of *15b*. Nitrosation of the mixture of *15c* and *15d* gave a mixture of *17c* and *17d* (eq 10), which was separated by crystallization (95% ethanol). 6,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime *17c* was found to be highly active as an antagonist for the glycine/NMDA receptor. It has a K_i value of $0.05 \mu\text{M}$, which is 439% of DCK. 5,6-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime *17d* was active as an antagonist for the glycine/NMDA receptor. It has a K_i value of $0.36 \mu\text{M}$, which is about 55% of DCK. 5,6,7-Trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime was also prepared and found to exhibit a K_i of $0.05 \mu\text{M}$, which is about 400% of DCK.

-23-




The acetyl derivative *18b* was prepared by reacting *17b* with acetic anhydride (eq 11). The reaction converts the ionizable NOH to an ester. It is possible that ester *18b* might pass the blood-brain barrier easier than *17b*. Ester *18b* was found to be active with a K_i of $0.16 \mu\text{M}$, which is 142% of DCK. The ester also might hydrolyze under physiological conditions to produce the highly active *17b in vivo*, thus *18b* may be a prodrug.



-24-

1,2,3,4-Tetrahydroquinoline-2,3,4-trione-4-oxime *14a* was prepared by nitrosation of 2,3-dihydroxyquinoline *11a*. Compound *11a* was prepared by ring expansion of isatin *10a* with diazomethane followed by hydrolysis (eq 12). 1,2,3,4-Tetrahydroquinoline-2,3,4-trione-4-oxime *14a* was found to be highly active with IC_{50} of $18.4 \mu M$, which is 14% of DCK. For all the known glycine/NMDA antagonists with no substituent in the benzene portion of the molecule, *14a* is among the most active.



Thus, the present invention is directed to compounds having high binding to the glycine receptor and low binding to the kainate and AMPA sites. Particular compounds of the invention may have high antagonist potency at the kainate, AMPA and quisqualate receptors in addition to the glycine receptor. According to the present invention, those compounds having high binding to the glycine receptor exhibit a glycine binding affinity (K_i) of about $100 \mu M$ or less in a glycine binding assay. Preferably, the compounds of the present invention exhibit a K_i of $10 \mu M$ or less. Most preferably, the compounds of the present invention exhibit a K_i of $1 \mu M$ or less. The compounds exhibit high binding to the kainate and AMPA sites if they exhibit a K_i of about $10 \mu M$ or less, especially, $1 \mu M$ or less in a kainate or AMPA binding assay.

-25-

The glycine antagonist potency *in vitro* may be determined using a 1 μ M glycine-stimulated [3 H]-MK801 binding assay. This assay takes advantage of the fact that the binding of [3 H]-MK801 to the PCP receptor inside the pore of the NMDA channel is dependent on the presence of both glutamate and glycine. In the absence of glycine but in the presence of glutamate, [3 H]-MK801 cannot bind effectively to the PCP receptor, because the NMDA channel remains closed and access of [3 H]-MK801 to the PCP receptor inside the closed channel pore is severely restricted.

The assay is conducted using rat brain membrane homogenates which are enriched in NMDA receptors. The membranes are prepared as follows. Frozen rat brains (obtained from Pel-Freez, Rogers, Arkansas) are homogenized in 15 volumes (w/v) of ice cold 0.32 M sucrose. The homogenate is spun at 1,000 x g for ten minutes. The supernatant is collected and spun for 20 minutes at 44,000 x g. The pellet is suspended in 15 volumes of water (relative to original brain weight). The homogenate is again spun at 44,000 x g for twenty minutes. The pellet is resuspended in 5 volumes of water and the suspension is freeze-thawed 2 times. After the final thaw cycle, the suspension is brought to 15 volumes with water and spun at 44,000 x g for twenty minutes. The pellet is resuspended in 5 volumes of ice-cold 10mM HEPES, and is titrated to pH 7.4 with KOH containing 0.04 % Triton X-100. Membranes are incubated with the Triton/HEPES buffer at 37°C for 15 minutes. The volume is then brought to 15 with ice-cold 10 mM HEPES, pH 7.4, and spun/washed three times with spins of 44,000 x g between washes. The final pellet is suspended in three volumes of 50 mM HEPES, pH 7.4 and the protein concentration is determined with a standard dye-binding protein assay (Bio-Rad, Richmond, CA). The suspension is stored at -80°C until used. Only HPLC grade water is used for all buffers and suspensions/washings. The extensive washings are necessary to remove as much endogenous glycine from the membrane preparation as possible.

On the day of the assay, the previously prepared membranes are thawed and 5 mM Tris/HCl buffer, pH 7.4, is added to yield a final protein

-26-

concentration of 0.156 mg/ml. For binding assays, 0.8 ml of membranes are pipetted into polypropylene tubes followed by 0.033 ml of 15.1 μ M 5,7-dichlorokynurenic acid (DCK), 0.033 ml of 30.3 μ M glycine in buffer (or buffer alone), 0.033 ml of 303 μ M glutamate in buffer (or for controls, 0.1 ml 1mM PCP instead of DCK/gly/glu), 0.033 ml glycine antagonist in buffer (or buffer alone) and 0.1 ml buffer containing 200,000 cpm [3 H]-MK801. Nonspecific binding is defined as the difference in binding that occurs in the absence or presence of PCP (final concentration: 100 μ M). To determine the effect of 1 μ M glycine on the binding of [3 H]-MK801, bound radioactivity in the presence of 10 μ M glutamate alone (final concentration) is subtracted from the bound radioactivity in the presence of both 10 μ M glutamate and 1 μ M glycine (final concentration). A 500 nM concentration (final) of 5,7-dichlorokynurenic (DCK) acid is added to all assay tubes. This concentration of the glycine antagonist DCK "buffers" most of the residual endogenous glycine that is not removed by the extensive washing steps that are carried out during the membrane preparation procedure. The 500 nM DCK does not interfere with the stimulation of [3 H]-MK801 binding that is effected by the addition of 1 μ M exogenous glycine.

The assays are incubated for 120 minutes at room temperature after which time the membrane-bound radioactivity is isolated from the free radioactivity by vacuum filtration through Whatman glass fiber filters that had been pretreated with 0.3% polyethyleneimine. Filtration is accomplished using a Brandel 48 well cell harvester. Filtered membranes are washed three times with 3 ml each of ice cold buffer. Filters are transferred to scintillation vials and 5 ml of scintillation cocktail is added. The vials are shaken overnight and the radioactivity is counted by liquid scintillation spectroscopy. The assays are done in triplicate and all experiments are conducted at least three times.

Inhibition dose response curves are constructed using increasing concentrations of glycine antagonists from 5 nM to 330 μ M. IC_{50} values are determined for compounds active in inhibiting 1 μ M glycine-stimulated [3 H]-MK801 binding by computer-assisted plotting of the inhibition curves and

-27-

interpolation. When compounds are found to inhibit glycine-stimulated [^3H]-MK801 binding, experiments are conducted to determine whether the inhibition of the glycine-stimulated [^3H]-MK801 binding is indeed mediated at the glycine binding site of the NMDA receptor. In these experiments, a fixed concentration of antagonist sufficient to produce a >95% inhibition of the 1 μM glycine-stimulated [^3H]-MK801 binding is incubated with the membranes without any additional glycine (above 1 μM) and in the presence of increasing concentrations of additional glycine (2 μM to 1 μM). If the inhibition of [^3H]-MK801 binding by the drug in the presence of 1 μM glycine is fully reversed by adding increasing concentrations of glycine, then the inhibition of [^3H]-MK801 binding is mediated by the drug acting as an antagonist at the glycine binding site of the NMDA receptor.

After constructing inhibition dose response curves and determination of glycine reversibility, K_i values for the glycine antagonists are calculated using the Cheng and Prusoff equation employing the experimentally determined IC_{50} values, the known concentration of glycine in the assay (1 μM) and the known affinity of glycine for the glycine binding site of the NMDA receptor (100 nM).

The same rat brain membrane homogenates used for the 1 μM glycine-stimulated [^3H]-MK801 binding assay are used for the [^3H]-AMPA radioligand binding assay. On the day of the assay the frozen membranes (prepared as described above) are thawed and diluted with 30mM Tris/HCl buffer containing 2.5 mM CaCl_2 and 100 mM KSCN, pH 7.4, to yield a final membrane concentration of 1.25 mg/ml membrane protein. For the binding assay, 0.8ml of membrane homogenate is added to polypropylene tubes followed by 0.033 ml drug and 0.067 ml buffer (or for controls by 0.1 ml buffer alone) and 0.1 ml buffer containing 200,000 cpm of [^3H]-AMPA. The assay is incubated for 30 minutes on ice. Bound radioactivity is separated from free radioactivity by filtration over Whatman glass fiber filters (pretreated with 0.3% polyethyleneimine) using a Brandel 48 well cell harvester.

Filtered membranes are washed three times with 3 ml each of ice cold buffer. The filters are transferred to scintillation vials and 5 ml of scintillation cocktail is added. The vials are shaken overnight and radioactivity is counted by liquid scintillation spectroscopy. Nonspecific binding is determined by the radioactivity that remains bound to the membranes in the presence of 10 mM glutamate. Inhibition dose response curves are constructed by adding increasing concentrations of drug from 10 nM to 100 μ M.

The same membrane preparation as that used for the [3 H]-AMPA binding assay may be used for the [3 H]-Kainate radioligand binding assay. On the day of the assay the frozen rat brain membranes are thawed and 5 mM Tris/HCl buffer, pH 7.4, is added to yield a final concentration of 0.5 mg/ml membrane protein. For the binding assay, 0.8 ml of membrane homogenate is added to polypropylene tubes followed by 0.033 ml drug and 0.067 ml buffer (or for controls by 0.1 ml buffer alone) and 0.1 ml buffer containing 200,000 cpm of [3 H]-kainate. The assay is incubated for 2 hours on ice. Bound radioactivity is separated from free radioactivity by filtration over Whatman glass fiber filters (pretreated with 0.3% polyethyleneimine) using a Brandel 48 well cell harvester. Filtered membranes are washed three times with 3 ml each of ice cold buffer. The filters are transferred to scintillation vials and 5 ml of scintillation cocktail is added. The vials are shaken overnight and radioactivity is counted by liquid scintillation spectroscopy. Nonspecific binding is determined by the radioactivity that remains bound to the membranes in the presence 10 mM glutamate. Inhibition dose response curves are constructed by adding increasing concentrations of drug from 250 nM to 330 μ M.

The anxiolytic activity of any particular compound of the present invention may be determined by use of any of the recognized animal models for anxiety. A preferred model is described by Jones, B.J. *et al.*, *Br. J. Pharmacol.* 93:985-993 (1988). This model involves administering the compound in question to mice which have a high basal level of anxiety. The test is based on the finding that such mice find it aversive when taken from a dark home

environment in a dark testing room and placed in an area which is painted white and brightly lit. The test box has two compartments, one white and brightly illuminated and one black and non-illuminated. The mouse has access to both compartments via an opening at floor level in the divider between the two compartments. The mice are placed in the center of the brightly illuminated area. After locating the opening to the dark area, the mice are free to pass back and forth between the two compartments. Control mice tend to spend a larger proportion of time in the dark compartment. When given an anxiolytic agent, the mice spend more time exploring the more novel brightly lit compartment and exhibit a delayed latency to move to the dark compartment. Moreover, the mice treated with the anxiolytic agent exhibit more behavior in the white compartment, as measured by exploratory rearings and line crossings. Since the mice can habituate to the test situation, naive mice should always be used in the test. Five parameters may be measured: the latency to entry into the dark compartment, the time spent in each area, the number of transitions between compartments, the number of lines crossed in each compartment, and the number of rears in each compartment. The administration of the compounds of the present invention is expected to result in the mice spending more time in the larger, brightly lit area of the test chamber.

In the light/dark exploration model, the anxiolytic activity of a putative agent can be identified by the increase of the numbers of line crossings and rears in the light compartment at the expense of the numbers of line crossings and rears in the dark compartment, in comparison with control mice.

A second preferred animal model is the rat social interaction test described by Jones, B.J. *et al.*, *supra*, wherein the time that two mice spend in social interaction is quantified. The anxiolytic activity of a putative agent can be identified by the increase in the time that pairs of male rats spend in active social interaction (90% of the behaviors are investigatory in nature). Both the familiarity and the light level of the test arena may be manipulated. Undrugged rats show the highest level of social interaction when the test arena

-30-

is familiar and is lit by low light. Social interaction declines if the arena is unfamiliar to the rats or is lit by bright light. Anxiolytic agents prevent this decline. The overall level of motor activity may also be measured to allow detection of drug effects specific to social behaviors.

5 The efficacy of the glycine and excitatory amino acid antagonists to inhibit glutamate neurotoxicity in rat brain cortex neuron cell culture system may be determined as follows. An excitotoxicity model modified after that developed by Choi (Choi, D.W., *J. Neuroscience* 7:357 (1987)) may be used to test anti-excitotoxic efficacy of the glycine and excitatory amino acid
10 antagonists. Fetuses from rat embryonic day 19 are removed from time-mated pregnant rats. The brains are removed from the fetuses and the cerebral cortex is dissected. Cells from the dissected cortex are dissociated by a combination of mechanical agitation and enzymatic digestion according to the method of Landon and Robbins (*Methods in Enzymology* 124:412 (1986)).
15 The dissociated cells are passed through an 80 micron nitex screen and the viability of the cells is assessed by Trypan Blue. The cells are plated on poly-D-lysine coated plates and incubated at 37°C in an atmosphere containing 91 % O₂/9% CO₂. Six days later, fluoro-d-uracil is added for two days to suppress non-neural cell growth. At culture day 12, the primary neuron cultures are
20 exposed to 100 µM glutamate for 5 minutes with or without increasing doses of glycine and excitatory amino acid antagonist or other drugs. After 5 minutes the cultures are washed and incubated for 24 hours at 37°C. Neuronal cell damage is quantitated by measuring lactate dehydrogenase (LDH) activity that is released into the culture medium. The LDH activity is
25 measured according to the method of Decker *et al.* (Decker *et al.*, *J. Immunol. Methods* 15:16 (1988)).

 The anticonvulsant activity of the glycine and excitatory amino acid antagonists may be assessed in the audiogenic seizure model in DBA-2 mice as follows. DBA-2 mice may be obtained from Jackson Laboratories, Bar
30 Harbor, Maine. These mice at an age of <27 days develop a tonic seizure within 5-10 seconds and die when they are exposed to a sound of 14 kHz

(sinus wave) at 110 dB (Lonsdale, D., *Dev. Pharmacol. Ther.* 4:28. (1982)).

Seizure protection is defined when animals injected with drug 30 minutes prior to sound exposure do not develop a seizure and do not die during a 1 minute exposure to the sound. 21 day old DBA-2 mice are used for all experiments.

5 Compounds are given intraperitoneally in either saline, DMSO or polyethyleneglycol-400. Appropriate solvent controls are included in each experiment. Dose response curves are constructed by giving increasing doses of drug from 1 mg/kg to 100 mg/kg. Each dose group (or solvent control) consists of at least six animals.

10 The anticonvulsant efficacy of the glycine receptor antagonists may be assessed in the pentylenetetrazol (PTZ)-induced seizure test as follows. Swiss/Webster mice, when injected with 50 mg/kg PTZ (i.p.) develop a minimal clonic seizure of approximately 5 seconds in length within 5-15 minutes after drug injection. Anticonvulsant efficacy of a glycine/excitatory amino acid antagonist (or other) drug is defined as the absence of a seizure
15 when a drug is given 30 minutes prior to PTZ application and a seizure does not develop for up to 45 minutes following PTZ administration. Glycine/excitatory amino acid antagonist or other drugs are given intraperitoneally in either saline, DMSO or polyethyleneglycol-400.
20 Appropriate solvent controls are included in each experiment. Dose response curves are constructed by giving increasing doses of drug from 1 mg/kg to 100 mg/kg. Each dose group (or solvent control) consists of at least six animals.

The efficacy of glycine/excitatory amino acid antagonists to protect
25 mice from NMDA-induced death may be assessed as follows. When mice are injected with 200 mg/kg N-methyl-D-aspartate (NMDA) i.p., the animals will develop seizures followed by death within 5-10 minutes. Glycine/excitatory amino acid antagonists are tested for their ability to prevent NMDA-induced death by giving the drugs i.p. 30 minutes prior to the NMDA application.
30 Glycine/excitatory amino acid antagonist or other drugs are given intraperitoneally in either saline, DMSO or polyethyleneglycol-400.


Appropriate solvent controls are included in each experiment. Dose response curves are constructed by giving increasing doses of drug from 1 mg/kg to 100 mg/kg. Each dose group (or solvent control) consists of at least six animals.

- 5 A series of different evaluations may be conducted on doses of the glycine/excitatory amino acid antagonists of the invention to determine the biological activity of the compounds both in normal gerbils and in animals exposed to 5 minutes of bilateral carotid occlusion. See Scheme I.

-33-

Scheme I

Gerbil Ischemia Model



-34-

These studies are conducted in animals who are conscious and have no other pharmacological agents administered to them. Gerbils are preinstrumented 48-hours prior to ischemia to allow for the complete elimination of the pentobarbital anesthetic which is employed. When tested with drugs, animals are given IP injections of the glycine/excitatory amino acid antagonist or vehicle. In the case of multiple injections, animals are given IP injections 2 hours apart and the final injection is given 30 minutes prior to the ischemic period or in the case of post treatment, the animals are given injections at 30 minutes, 2 hours, 4 hours and 6 hours post-ischemic reperfusion.

In order to assess the direct pharmacological activity or potential activity of the glycine/excitatory amino acid antagonists, naive gerbils are injected with either saline or differing doses of the antagonist. The behavioral changes are assessed using a photobeam locomotor activity chamber which is a two foot circular diameter arena with photobeam detection. Animals are individually placed in the 2 foot diameter chambers. The chambers are housed in a cabinet which is closed and noise is abated using both a background white noise generator and a fan. Animals are placed in these chambers in the case of the initial pharmacological evaluation for a period of 6 hours and the total activity during each successive hour is accumulated using the computer control systems.

Saline results in an initial high rate of activity, with the control animals showing a first hour activity level of about 1600 counts. This level of control activity is typical for the gerbil under these experimental conditions. As the session progressed, animals decrease their exploratory activity and at the terminal period the activity declines to about 250 counts per hour. It is expected that the glycine/excitatory amino acid antagonists of the present invention will have no significant effect on either the initial exploratory rate or the terminal rate of exploration.

In a next phase of the evaluation of the glycine/excitatory amino acid antagonists, gerbils are pretreated with varying doses of the antagonists and

then exposed to a five minute period of bilateral carotid occlusion. Following the initiation of reperfusion, animals are placed into the circular locomotor activity testing apparatus and the activity at the beginning of the first hour following reperfusion is monitored for the subsequent four hours.

5 Control animals not exposed to ischemia and given injections of saline prior to being placed in the locomotor activity chamber show a characteristic pattern of activity which in the first hour of locomotor activity is substantially higher than during all other hours and progressively declined over the four
10 hours to a very low value. In contrast to the progressive decline in activity over the four hour testing period, control animals that are exposed to five minutes of cortical ischemia demonstrate a completely different pattern of locomotor activity. During the first hour there is a significant decline in activity which is followed by a progressive increase in which the activity
15 during the fourth hour is ten-fold higher than that demonstrated by animals not exposed to carotid occlusion. These results are typical and are a reliable result of the alterations caused by five minutes of bilateral carotid occlusion in the gerbil.

 Separate groups of gerbils are pretreated with the glycine/excitatory amino acid antagonists of the invention 30 minutes before the onset of carotid
20 occlusion and then placed into the locomotor activity following one hour of reperfusion. It is expected that pretreatment of the gerbils with the glycine/-excitatory amino acid antagonists of the invention will prevent both the post-ischemic decrease and increase in activity. Post-ischemic decreases in activity are expected to be near zero during the first hour following reperfusion.
25 Pretreatment with the glycine/excitatory amino acid antagonists of the invention is expected to reduce or prevent this early depression of behavior. In addition, the glycine/excitatory amino acid antagonists of the invention are expected to prevent the post-ischemic stimulation of behavior.

 Subsequent to completion of the single dose pretreatment evaluations,
30 gerbils are also evaluated with multiple injections of the glycine/excitatory amino acid antagonists of the invention. Doses are administered I.P. at 6

hours, 4 hours, 2 hours and 30 minutes prior to the onset of 5 minutes of ischemia.

At 24 hours all animals are evaluated for differences in patrolling behavior using an 8-arm radial maze. In this procedure, animals are placed
5 into the center start chamber of the maze, the barrier removed and the amount of time and the number of times the animal makes an error recorded prior to completion of exploration in all 8 arms of the maze. An error is defined as the revisiting of an arm by entering to the extent of the entire body without including tail by the animal. If the animal perseveres or fails to leave the arm
10 for longer than five minutes, the session is terminated. In the control population of the animals, the number of errors and exploration of the maze with no prior experience (naïve) is approximately 6 errors. This is an average value for an N of 28 gerbils. Following 5 minutes of bilateral carotid occlusion and testing at 24 hours, gerbils make an average number of errors
15 of 21. When animals are pretreated with the glycine/excitatory amino acid antagonists of the invention, there is expected to be a significant reduction in the number of errors made. There is also expected to be a significant sparing of the behavioral changes that are induced in the radial arm maze performance.

20 It is also expected that post treatment the glycine/excitatory amino acid antagonists of the invention will reduce the short term memory impairment 24 hours post ischemic/reperfusion.

The effects of 5 minutes of bilateral carotid occlusion on neuronal cell death in the dorsal hippocampus may be evaluated in animals 7 days after
25 ischemia reperfusion injury. Previous studies have demonstrated that neuronal degeneration begins to occur around 3 days following cerebral ischemia. By 7 days those neurons which have been affected and will undergo cytolysis and have either completed degeneration or are readily apparent as dark nuclei and displaced nuclei with eosinophilic cytoplasm with pycnotic nuclei. The lesion
30 with 5 minutes of ischemia is essentially restricted within the hippocampus to the CA1 region of the dorsal hippocampus. The intermedial lateral zone of

-37-

the horn is unaffected and the dentate gyrus and/or in CA3 do not show pathology. Gerbils are anesthetized on day 7 following ischemia with 60 mg/kg of pentobarbital. Brains are perfused transcardiac with ice-cold saline followed by buffered paraformaldehyde (10%). Brains are removed,
5 imbedded and sections made. Sections are stained with hematoxylin-eosin and neuronal cell counts are determined in terms of number of neuronal nuclei/100 micrometers. Normal control animals (not exposed to ischemia reperfusion injury) will not demonstrate any significant change in normal density nuclei within this region. Exposure to five minutes of bilateral carotid occlusion
10 results in a significant reduction in the number of nuclei present in the CA1 region. In general, this lesion results in a patchy necrosis instead of a confluent necrosis which is seen if 10 minutes of ischemia is employed. Pretreatment with the glycine receptor antagonists of the invention are expected to produce a significant protection of hippocampal neuronal
15 degeneration.

It is known that NMDA receptors are critically involved in the development of persistent pain following nerve and tissue injury. Tissue injury such as that caused by injecting a small amount of formalin subcutaneously into the hindpaw of a test animal has been shown to produce
20 an immediate increase of glutamate and aspartate in the spinal cord (Skilling, S.R., *et al.*, *J. Neurosci.* 10:1309-1318 (1990)). Administration of NMDA receptor blockers reduces the response of spinal cord dorsal horn neurons following formalin injection (Dickenson and Aydar, *Neuroscience Lett.* 121:263-266 (1991); Haley, J.E., *et al.*, *Brain Res.* 518:218-226 (1990)).
25 These dorsal horn neurons are critical in carrying the pain signal from the spinal cord to the brain and a reduced response of these neurons is indicative of a reduction in pain perceived by the test animal to which pain has been inflicted by subcutaneous formalin injection.

Because of the observation that NMDA receptor antagonists can block
30 dorsal horn neuron response induced by subcutaneous formalin injection, NMDA receptor antagonists have potential for the treatment of chronic pain

-38-

such as pain which is caused by surgery or by amputation (phantom pain) or by infliction of other wounds (wound pain). However, the use of conventional NMDA antagonists such as MK801 or CGS 19755, in preventing or treating chronic pain, is severely limited by the adverse PCP-like behavioral side effects that are caused by these drugs. It is expected that the glycine receptor antagonists that are the subject of this invention will be highly effective in preventing chronic pain in mice induced by injecting formalin subcutaneously into the hindpaw of the animals. Because the glycine/excitatory amino acid antagonists of this invention are expected to be free of PCP-like side effects, these drugs are highly useful in preventing or treating chronic pain without causing PCP-like adverse behavioral side effects.

The effects of the glycine receptor antagonists of the present invention on chronic pain may be evaluated as follows. Male Swiss/Webster mice weighing 25-35 grams are housed five to a cage with free access to food and water and are maintained on a 12 hour light cycle (light onset at 0800h). The glycine receptor antagonist is dissolved in DMSO at a concentration of 1-40 and 5-40 mg/ml, respectively. DMSO is used as vehicle control. All drugs are injected intraperitoneally (1 μ l/g). The formalin test is performed as described (Dubuisson and Dennis, *Pain* 4:H161-174 (1977)). Mice are observed in a plexiglass cylinder, 25cm in diameter and 30cm in height. The plantar surface of one hindpaw is injected subcutaneously with 20 μ l of 5% formalin. The degree of pain is determined by measuring the amount of time the animal spends licking the formalin-injected paw during the following time intervals: 0-5' (early phase); 5'-10', 10'-15' and 15'-50' (late phase). To test whether the glycine/excitatory amino acid antagonists prevent chronic pain in the test animals, vehicle (DMSO) or drugs dissolved in vehicle at doses of 1mg/kg to 40mg/kg are injected intraperitoneally 30 minutes prior to the formalin injection. For each dose of drug or vehicle control at least six animals are used.

Compared to vehicle control, it is expected that the intraperitoneal injection of the glycine receptor antagonists 30 minutes prior to formalin

injection into the hindpaw will significantly inhibit formalin-induced chronic pain in a dose-dependent manner as determined by the reduction of the time spent licking by the mouse of the formalin injected hindpaw caused by increasing doses of glycine/excitatory amino acid antagonist.

5 Compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is with the skill of the art. Typically, the compounds may be
10 administered to mammals, e.g., humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for anxiety disorders, e.g., generalized anxiety disorder, phobic disorders, obsessional compulsive disorder, panic disorder, and post traumatic stress disorders.
15 Preferably, about 0.01 to about 10 mg/kg is orally administered to treat or prevent such disorders. For intramuscular injection, the dose is generally about one-half of the oral dose. For example, for treatment or prevention of anxiety, a suitable intramuscular dose would be about 0.0025 to about 15 mg/kg, and most preferably, from about 0.01 to about 10 mg/kg.

20 In the method of treatment or prevention of neuronal loss in ischemia, brain and spinal cord trauma, hypoxia, hypoglycemia, and surgery, as well as for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's Syndrome, or in a method of treating a disease in which the pathophysiology of the disorder involves hyperactivity of
25 the excitatory amino acids or NMDA receptor-ion channel related neurotoxicity or psychosis, the pharmaceutical compositions of the invention may comprise the compounds of the present invention at a unit dose level of about 0.01 to about 50 mg/kg of body weight, or an equivalent amount of the pharmaceutically acceptable salt thereof, on a regimen of 1-4 times per day.
30 When used to treat chronic pain or to induce anesthesia, the compounds of the invention may be administered at a unit dosage level of from about 0.01 to

-40-

about 50mg/kg of body weight, or an equivalent amount of the pharmaceutically acceptable salt thereof, on a regimen of 1-4 times per day. Of course, it is understood that the exact treatment level will depend upon the case history of the animal, e.g., human being, that is treated. The precise
5 treatment level can be determined by one of ordinary skill in the art without undue experimentation.

The unit oral dose may comprise from about 0.01 to about 50 mg, preferably about 0.1 to about 10 mg of the compound. The unit dose may be administered one or more times daily as one or more tablets each containing
10 from about 0.1 to about 10, conveniently about 0.25 to 50 mg of the compound or its solvates.

In addition to administering the compound as a raw chemical, the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising
15 excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically. Preferably, the preparations, particularly those preparations which can be administered orally and which can be used for the preferred type of administration, such as tablets, dragees, and capsules, and also preparations which can be
20 administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally, contain from about 0.01 to 99 percent, preferably from about 0.25 to 75 percent of active compound(s), together with the excipient.

Also included within the scope of the present invention are the non-
25 toxic pharmaceutically acceptable salts of the compounds of the present invention. Basic salts are formed by mixing a solution of the particular 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oxime the present invention with a solution of a pharmaceutically acceptable non-toxic base such as sodium hydroxide, potassium hydroxide, choline hydroxide, sodium bicarbonate,
30 sodium carbonate, Tris and the like.

-41-

The pharmaceutical compositions of the invention may be administered to any animal which may experience the beneficial effects of the compounds of the invention. Foremost among such animals are humans, although the invention is not intended to be so limited.

5 The pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal or ocular routes. Alternatively, or concurrently, administration may be by the oral route. The dosage
10 administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

 When the compositions of the invention are administered ocularly, one may achieve either local or systemic administration. For example, the
15 compositions of the present invention may be administered in the form of eye drops which are substantially isotonic with tear fluid to achieve systemic administration. Preferably, such compositions will also comprise a permeation-enhancing agent which aids the systemic absorption of the compounds of the present invention. See, U.S. Patent No. 5,182,258.
20 Alternatively, the compositions of the invention may be administered ocularly to treat or prevent optic nerve degeneration. In this embodiment, the compounds of the present invention are administered in the form of eye drops, as disclosed above, or may be injected into the vicinity of the optic nerve. In the alternative, thin ocular implants may be employed which slowly release the
25 compounds of the present invention.

 In addition to the pharmacologically active compounds, the new pharmaceutical preparations may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
30 Preferably, the preparations, particularly those preparations which can be administered orally and which can be used for the preferred type of

administration, such as tablets, dragees, and capsules, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally, are present at a concentration of from about 0.01 to 99 percent, together with the excipient.

5 The pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the
10 resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.

 Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen
15 phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross-
20 linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to
25 gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetyl-
30 cellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for

example, for identification or in order to characterize combinations of active compound doses.

Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.

Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.

Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts and alkaline solutions. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400 (the compounds are soluble in PEG-400). Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.

The characterization of glycine binding sites *in vitro* has been difficult because of the lack of selective drug ligands. Thus, the glycine ligands of the present invention may be used to characterize the glycine binding site.

Particularly preferred substituted and unsubstituted 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes which may be used for this purpose are isotopically radiolabelled derivatives, e.g., where one or more of the atoms are replaced with ^3H , ^{11}C , ^{14}C , ^{15}N , or ^{18}F .

The following examples are illustrative, but not limiting, of the method and compositions of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.

Examples

Example 1 Preparation of 1,2,3,4-Tetrahydroquinoline-2,3,4-trione-3-oxime (17a)

To a mixture of 3.21 g (19.9 mmol) of 2,4-quinolinediol (Aldrich) and 1.87 g (27.1 mmol) of NaNO₂ in 60 mL of 0.2 N NaOH in an ice-bath was added dropwise 40 mL of aqueous 2N H₂SO₄. The mixture was stirred in the ice-bath for 1 h after addition of H₂SO₄, filtered and dried to leave 3.41 g of orange solid which was crystallized by boiling with 150 mL of ethanol (95%) and filtered. The filtrate was cooled to and kept at room temperature for 5 h. The crystalline precipitate was filtered and dried to leave 1.88 g (50%) of *17a* as a red solid, mp 206°C (decomposed, lit 208°C, dec.). ¹H NMR (CDCl₃ + DMSO-d₆), 6.65-6.78 (m, 2), 7.15 (m, 1), 7.556 (d, 0.30, *J* = 8.1), 7.605 (d, 0.70, *J* = 8.1), 10.887 (s, 0.3), 11.346 (s, 0.7). MS, 190 (100, M⁺), 173 (25), 146 (55). High resolution MS, Calcd for C₉H₆N₂O₃, 190.0375, found 190.0400.

Example 2 Preparation of 5,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (17b)

5,7-Dichloro-2,4-quinolinediol (15b). A solution of 11.6 g (71.6 mmol) of 3,5-dichloroaniline and 26.3 g (164 mmol) of diethyl malonate

-45-

was heated at 180°C for 6 h and the ethanol produced was collected (~3.5 mL). The solution was cooled to room temperature and precipitate was observed. The mixture was filtered and washed with methanol (40 mL). The filtrate was mixed with 26 g of Na₂CO₃ and 200 mL of water and refluxed for 1 h. The solution was acidified with aqueous 2N HCl in an ice-bath to pH = 1. The mixture was filtered and washed with water, and dried to leave a white solid (13.9 g). The solid was mixed with 150 mL of polyphosphoric acid and heated at 140°C for 3 h. The solution was cooled to room temperature and diluted with 200 mL of aqueous 1N HCl. The mixture was stirred for 4 h, then neutralized with aqueous 20% NaOH to pH = 4. It was filtered and washed with water, and dried to leave 12.3 g (74%) of *15b* as white solid, mp 360-361°C (decomposed). ¹H NMR (CDCl₃ + DMSO-d₆), 5.447 (s, 1), 6.620 (d, 1, *J* = 1.84), 6.804 (d, 1, *J* = 1.86), 10.915 (sb, 1). MS, 229 (100, M⁺), 187 (80), 160 (30), 124 (20). High resolution MS, Calcd for C₉H₅³⁵Cl₂NO₂ 228.9694, found 228.9709.

5,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (*17b*).
To a mixture of 147 mg (0.616 mmol) of 5,7-dichloro-2,4-quinolinediol (*15b*) and 126 mg (1.82 mmol) of NaNO₂ in 3 mL of 0.2 N NaOH in an ice-bath was added dropwise 2 mL of aqueous 2N H₂SO₄. The mixture was stirred in the ice-bath for 4 h after addition of H₂SO₄, filtered and dried to leave an orange solid. The solid was crystallized by boiling with 10 mL of ethanol (95%). The solution was cooled to room temperature, filtered and dried to leave 132 mg (83%) of *17b* as a yellow solid, mp 244-245°C (decomposed). ¹H NMR (CDCl₃ + DMSO-d₆), 7.011 (d, 0.44, *J* = 1.8), 7.080 (m, 1.54), 11.567 (sb, 0.35), 11.821 (s, 0.46). MS, 258 (100, M⁺), 241 (60), 214 (80), 187 (20), 160 (30). High resolution MS, Calcd for C₉H₄³⁵Cl₂N₂O₃, 257.9595, found 257.9598.

Example 3 Preparation of 6,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (17c) and 5,6-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (17d)

6,7-Dichloro-2,4-quinolinediol (*15c*) and 5,6-dichloro-2,4-quinolinediol (*15d*). A solution of 9.75 g (60.2 mmol) of 3,4-dichloroaniline and 21.1 g (132 mmol) of diethyl malonate was heated at 180°C under N₂ for 30 h. It was cooled to room temperature, filtered and washed with 10 mL of methanol. The filtrate was mixed with 15 g of Na₂CO₃, 30 mL of water and 10 mL of methanol and refluxed for 1 h. The mixture was acidified with aqueous 6N HCl in an ice-bath to pH = 1. The precipitate was filtered and washed with water, and dried to leave a white solid (9.4 g). ¹H NMR (CDCl₃ + DMSO-d₆), 3.099 (s, 2), 7.028 (d, 1, *J* = 8.75), 7.128 (dd, 1, *J* = 2.26, 8.70), 7.619 (d, 1, *J* = 2.23), 9.800 (s, 1). The solid was mixed with 100 mL of polyphosphoric acid and heated at 140°C for 3 h. The solution was cooled to room temperature and diluted with 100 mL of aqueous 1N HCl and 300 mL of water in an ice-bath. The mixture was then neutralized in the ice-bath with aqueous 20% NaOH to pH = 4. The mixture was filtered and washed with water, and dried to leave 8.2 g (95%) of pale-yellow solid as a mixture of *15c* and *15d*. ¹H NMR (CDCl₃ + DMSO-d₆), *15c*: 5.513 (s, 1), 7.050 (s, 1), 7.510 (s, 1), 10.861 (sb, 1); *15d*: 5.597 (s, 1), 6.846 (d, 1, *J* = 9.0), 7.066 (d, 1, *J* = 9.0), 10.9 (sb, 1); *15c*:*15d* = 1:1. A portion (800 mg) of the mixture was dissolved in 15 mL of aqueous 1N NaOH and filtered. The filtrate was acidified with aqueous 2N HCl to pH = 8.2 to give a solid precipitate. It was filtered, washed with water and dried to leave a white solid. ¹H NMR shows *15c*:*15d* = 1:1. The aqueous solution was acidified to pH = 8.0 to give more precipitate. It was filtered, washed with water and dried to leave a white solid. ¹H NMR shows *15c*:*15d* = 1:1. The aqueous solution was acidified to pH = 4.0 to give more precipitate. It was filtered, washed with water and dried to leave a white solid. ¹H NMR shows *15c*:*15d* = 1:0.7.

6,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (*17c*) and 5,6-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime (*17d*).

A mixture of 113 mg (0.491 mmol) of *15c* and *15d* and 120 mg (1.73 mmol) of NaNO₂ in 3 mL of 0.2 N NaOH was stirred for 30 min. To the resulting solution was added dropwise 1 mL of 2 N H₂SO₄. The resulting red mixture was stirred overnight, filtered and washed with water, and dried to leave 111 mg of yellow solid. ¹H NMR shows *17c*:*17d* = 1:1. The solid was boiled with 15 mL of 95% ethanol and 2 mL of acetone and the mixture was filtered. The solid in the filter was dried to leave 20 mg (15.7%) of *17c* as a yellow solid, mp > 250°C. ¹H NMR (CDCl₃ + DMSO-d₆), 6.89 (m, 1), 7.66 (s, 0.4), 7.73 (s, 0.6), 11.10 (s, 0.4), 11.55 (s, 0.6). Solid precipitate was observed in the filtrate after it was cooled to room temperature. It was filtered and washed with a minimum amount of ethanol, and dried to leave 37 mg of yellow solid which is a mixture of *17c* and *17d* as determined by ¹H NMR. More solid was observed in the filtrate, it was filtered and dried to leave 40 mg (31%) of *17d* as yellow-orange solid, mp 218-129°C. ¹H NMR (CDCl₃ + DMSO-d₆), 6.98 (m, 1), 7.42 (m, 1), 11.30 (s, 0.4), 11.70 (s, 0.6).

Example 4 Preparation of 5,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-acetyloxime (*18b*).

To a solution of 201 mg (0.776 mmole) of *17b* in 2 mL of DMSO was added 0.4 mL of acetic anhydride and the solution was stirred overnight. Solid precipitate was observed after about 1 hr. To the mixture was added 10 mL of ice-water and the mixture was stirred until all of the ice melted. The mixture was filtered and washed with water, and dried to leave 228 mg (97%) of *18b* as a yellow solid, mp 194-195°C. ¹H NMR (DMSO-d₆), 2.292 (s, 3), 7.095 (m, 1), 7.34 (m, 1), 11.39 (s, 0.4), 11.51 (s, 0.6).

Example 5 Preparation of 1,2,3,4-Tetrahydroquinoline-2,3,4-trione-4-oxime (14a)

2,3-quinolinediol (*11a*). To a mixture of 1.05 g (7.1 mmol) of isatin (Aldrich) in 15 mL of ether kept in an ice-bath was added in one portion a solution of diazomethane in ether (prepared from 4.4 g of Diazald, containing approximately 13 mmol of diazomethane). The mixture was stirred in an ice-bath for 3 h, then at 25°C overnight. It was filtered and dried to leave a white solid 0.648 g (52%), mp 184-185°C. ¹H NMR, 3.977 (s, 3), 7.014 (s, 1), 7.21 (m, 1), 7.39 (m, 2), 7.509 (d, 1, *J* = 7.8), 11.429 (s, 1). A solution of 301 mg of the above white solid in 1 mL of acetic acid and 1 mL of 48% HBr was refluxed for 2 days. It was cooled to room temperature to give a solid precipitate which was diluted with 2 mL of water, filtered and washed with water, and dried to leave an almost colorless solid. The solid was dissolved in 2 mL of 2N NaOH to form a clear solution. It was acidified by the addition dropwise of 1N HCl to pH = 6. The white precipitate was filtered and washed with water, and dried to leave 250 mg (90%) of *11a* as a white solid, mp 261-262°C. ¹H NMR (CDCl₃ + DMSO-d₆), 6.618 (s, 1), 6.698 (t, 1, *J* = 7.5), 6.809-6.901 (m, 2), 6.985 (d, 1, *J* = 7.8), 8.061 (s, 1), 11.448 (s, 1).

1,2,3,4-Tetrahydroquinoline-2,3,4-trione-4-oxime (*14a*). To a solution of 50.1 mg (0.311 mmol) of *11a* and 52.0 mg (0.753 mmol) of NaNO₂ in 1.5 mL of aqueous 0.2N NaOH in an ice-bath was added dropwise 1 mL of aqueous 2N H₂SO₄. A red precipitate was observed. The mixture was stirred in the ice-bath for 2 h and at 25°C for 4 h, filtered and washed with water, and dried to leave 37 mg (62%) of *14a* as a red solid, mp 241-242°C. ¹H NMR (CDCl₃ + DMSO-d₆), 6.83 (m, 2), 7.069 (t, 1, *J* = 7.2), 8.544 (d, 1, *J* = 8.1), 11.228 (m, 1). MS, 190 (100, M⁺), 162 (50), 145 (65), 117 (30). High resolution MS, Calcd for C₉H₆N₂O₃ 190.0375, found 190.0377.

Example 6 Preparation of 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime

3,4,5-Trichloroaniline monomalonamide. To a solution of 3,4,5-trichloroaniline (393 mg, 2.0 mmol) and triethylamine (680 mg, 6.7 mmol) in 30 mL of anhydrous ether was added a solution of methyl malonyl chloride (920 mg, 7.4 mmol) in 10 mL of anhydrous ether dropwise with stirring at 25°C under N₂. After this addition, the resulting mixture was stirred at 25°C for 16 h. then 20 mL of 0.5 N aq. HCl was added and stirred for 0.5 h.

The mixture was poured into a separatory funnel, the organic layer was separated and the aqueous layer was extracted with ether (3 x 15 mL). The ether extracts were combined and washed with brine and rota-evaporated to dryness. To the residue (white solid) was added 50 mL of methanol and 10 mL of 1 N aq. NaOH, the mixture was refluxed for 3 h, allowed to cool to 25°C, acidified with 1N HCl to pH 2-3 (pH test paper), and the solvents were removed by rotary evaporation. To the residue was added ether (30 mL) and H₂O (10 mL), the mixture was stirred vigorously, then poured into a separatory funnel. The ether layer was separated, and the aqueous layer was extracted with ether (3 x 15 mL). The ether extracts were combined, washed with brine (2 x 10 mL), dried over Na₂SO₄, and rota-evaporated to dryness giving a yellowish solid, which was crystallized from CHCl₃ (about 30 mL) affording 473 mg (84%) of 3,4,5-trichloroaniline monomalonamide as an amorphous off-white powder: Mp 155-6°C. IR 3422, 3316, 3183, 3123, 1722, 1649, 1609, 1583, 1536, 1438, 1238 cm⁻¹. ¹H NMR (DMSO-d₆) 12.78 (bs, 1H), 10.533 (s, 1H), 7.823 (s, 2H), 3.368 (s, 2H) ppm.

5,6,7-Trichloro-2,4-quinolinediol. Patel, G.H. *et al.*, *J. Soc. Ind. Res.* 19:436 (1960). A mixture of 454 mg (1.6 mmol) of 3,4,5-trichloroaniline monomalonamide and about 15 mL of polyphosphoric acid was stirred at 160°C for 3 h. The resulting clear solution was allowed to cool to 25°C, 1 N HCl (70 mL) was added with stirring, then 1N NaOH was added with stirring to adjust the pH to 4 (pH test paper). The precipitate was collected

by vacuum filtration, washed with H₂O (5 x 10 mL), dried at 40°C under 0.1 mmHg for 8 h giving 406 mg (96%) of the crude product (by NMR) as a light brown powder, which was dissolved in DMSO (10 mL) and precipitated with H₂O (40 mL). The precipitate was collected by vacuum filtration, washed with H₂O (6 x 10 mL) thoroughly, dried at 40°C under 0.1 mmHg for 8 h giving 303 mg (71%) of 5,6,7-trichloro-2,4-quinolinediol as a cream-colored powder. Mp. 303-5°C (dec.) IR 3435, 3130, 1656, 1629, 1569, 1284 cm⁻¹. ¹H NMR (DMSO) 11.656 (s, 1H), 11.506 (s, 1H), 7.422 (s, 1H), 5.778 (s, 1H) ppm.

5,6,7-Trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime. (Wheeler, T.N. *et al.*, *J. Org. Synth. Coll.* 6:841 (1988)). To a solution of 228 mg (0.86 mmol) of 5,6,7-trichloro-2,4-quinolinediol in t-BuOH (15 mL) were added t-BuOK (488 mg, 4.35 mmol) and i-amyl nitrite (0.585 mL, 4.35 mmol). The resulting mixture was stirred for 12h at 25°C under N₂, then cooled water (10 mL) was added slowly with stirring. To the resulting deep yellow solution was added 0.5 N HCl to adjust the pH to 2. The precipitate was collected by vacuum filtration, washed with H₂O (6 x 10 mL), dried at 40°C under 0.1 mmHg for 10 h giving 220 mg (87%) of 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime as a yellow powder. Mp 251°C (dec.). IR 3435, 3236, 1676, 1584, 1526 cm⁻¹. ¹H NMR (DMSO-d₆) 11.432 (s, 0.5 H), 11.339 (s, 0.5 H), 7.313 (s, 1 H) ppm. HRMS for C₉H₃Cl₃N₂O₃: Calcd. 291.9210, Found, 291.9213.

Example 7 *In Vivo* Anticonvulsant Activity


5,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime was evaluated for anticonvulsant activity after i.p. administration in the mouse maximum electroshock seizure model. Mice, 30-35 g (male) were injected i.p. with 70 mg/kg of the drug dissolved in DMSO (1 ul/g). Ten mice each were used in the drug and control groups. The control group was injected with an equal volume of DMSO. Seizures were elicited by stimulation with corneal electrodes. The stimulation parameters for eliciting the seizures were

-51-

as follows: 50mA, 60 pulses/second square wave, 0.8 ms pulse width, 0.2 sec length of stimulus. Under these conditions, 100% of control animals developed tonic hindlimb extension immediately after the corneal electrical stimulation. A Hugo Basile electroshock seizure stimulator was used for these experiments. The seizure stimulus was applied 1 hour after injection of the drug. Under these conditions, the drug prevented seizures from occurring in 8 out of 10 animals injected with drug. No seizure protection was seen in the control (DMSO-only) group.

Example 8 *In Vitro* Binding Assay

Table 1 shows the results of binding assays at the glycine binding site for a number of 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 and 4-oximes.

							
Drug	R ₁	R ₂	R ₃	R ₄	X	Y	K _i Gly (μM)
14a	H	H	H	H	NOH	O	1.7
17b	Cl	H	Cl	H	O	NOH	0.02
17c	H	Cl	Cl	H	O	NOH	0.05
17d	Cl	Cl	H	H	O	NOH	0.36
17e	Cl	Cl	Cl	H	O	NOH	0.05
18b	Cl	H	Cl	H	O	NOCOCH ₃	0.15


Having now fully described this invention, it will be understood to those of ordinary skill in the art that the same can be performed within a wide

and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents and publications cited herein are fully incorporated by reference herein in their entirety.

-53-

What Is Claimed Is:

1. A method of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia or surgery, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula




(I)

- or a pharmaceutically acceptable salt thereof;
 wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and
- 10 R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocycloxy group, aralkoxy or
- 15 haloalkoxy.

2. The method of claim 1, wherein said compound has the formula:

-54-



(II)


or a pharmaceutically acceptable salt thereof.

3. The method of claim 2, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

5 4. The method of claim 2, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

5. The method of claim 1, wherein said compound is 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

6. The method of claim 1, wherein said compound has the formula



(III)

or a pharmaceutically acceptable salt thereof.

-55-


7. The method of claim 1, wherein said neuronal loss occurs as a result of air bubbles that lodge in the brain during or immediately after surgery.

8. The method of claim 1, wherein said neuronal loss occurs as a result of cardiopulmonary bypass surgery.

9. The method of claim 1, wherein said neuronal loss occurs as a result of carotid endarterectomy surgery.

10. The method of claim 1, wherein said neuronal loss occurs as a result of multiple strokes resulting in dementia.

11. A method of treating or preventing a neurodegenerative disease selected from Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula



(I)


or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy,

heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy or haloalkoxy.

12. The method of claim 11, wherein said compound has the formula



(II)

or a pharmaceutically acceptable salt thereof.


13. The method of claim 12, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

14. The method of claim 12, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

15. The method of claim 12, wherein said compound is 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

16. The method of claim 11, wherein said compound has the formula


-57-



(III)

or a pharmaceutically acceptable salt thereof.

17. A method of treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula



(I)


or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloxy; and

R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocycloxy group, aralkoxy or haloalkoxy.

-58-

18. The method of claim 17, wherein said compound has the formula



(II)


or a pharmaceutically acceptable salt thereof.

5 19. The method of claim 18, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

20. The method of claim 18, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

10 21. The method of claim 18, wherein said compound is 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

22. The method of claim 17, wherein said compound has the formula




(III)

-59-

or a pharmaceutically acceptable salt thereof.

23. A method of treating or preventing chronic pain, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula:




(I)

or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

10 $R_1 - R_4$ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocycloxy group, aralkoxy or haloalkoxy.

15 24. The method of claim 23, wherein said compound has the formula



(II)

-60-


or a pharmaceutically acceptable salt thereof.

25. The method of claim 24, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

5 26. The method of claim 24, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

27. The method of claim 24, wherein said compound is 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

28. The method of claim 23, wherein said compound has the formula




(III)

or a pharmaceutically acceptable salt thereof.

29. A method of treating or preventing anxiety, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula

-61-




(I)

or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy or haloalkoxy.

30. The method of claim 29, wherein said compound has the formula



(II)

or a pharmaceutically acceptable salt thereof.


31. The method of claim 30, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

-62-

32. The method of claim 30, wherein said compound is 5,7-dichloro-2,3,4-quinoline-2,3,4-trione-3-oxime.

33. The method of claim 30, wherein said compound is 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.


5 34. The method of claim 29, wherein said compound has the formula



(III)

or a pharmaceutically acceptable salt thereof.

10 35. A method of treating or preventing convulsions, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula



(I)


-63-

or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

- 5 R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocycloxy group, aralkoxy or haloalkoxy.

- 10 36. The method of claim 35, wherein said compound has the formula



(II)

or a pharmaceutically acceptable salt thereof.


- 15 37. The method of claim 36, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

38. The method of claim 36, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

39. The method of claim 36, wherein said compound is 5,6,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

-64-


40. The method of claim 35, wherein said compound has the formula



(III)

or a pharmaceutically acceptable salt thereof.

5 41. A method of inducing anesthesia, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula:



(I)

or a pharmaceutically acceptable salt thereof;


10 wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloxy; and

15 $R_1 - R_4$ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy,

-65-

heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy or haloalkoxy.

42. The method of claim 41, wherein said compound has the formula



(II)

or a pharmaceutically acceptable salt thereof.


43. The method of claim 42, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

44. The method of claim 42, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

45. The method of claim 42, wherein said compound is 5,6,7-dichloro-2,3,4-quinoline-2,3,4-trione-3-oxime.

46. The method of claim 41, wherein said compound has the formula


-66-



(III)

or a pharmaceutically acceptable salt thereof.

47. A method of treating or preventing psychosis, comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula:



(I)


or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocycloxy group, aralkoxy or haloalkoxy.

-67-

48. The method of claim 47, wherein said compound has the formula



(II)


or a pharmaceutically acceptable salt thereof.

5 49. The method of claim 48, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

50. The method of claim 48, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

10 51. The method of claim 48, wherein said compound is 5,6,7-dichloro-2,3,4-quinoline-2,3,4-trione-3-oxime.

52. The method of claim 47, wherein said compound has the formula




(III)

-68-

or a pharmaceutically acceptable salt thereof.

53. The method of any one of claims 1, 11, 17, 23, 29, 35, 41 and 47, wherein said compound is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

5 54. A compound having the Formula:



(I)

or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

10 R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy or

15 haloalkoxy;
with the proviso that at least one of R₁ and R₃ is other than hydrogen.

55. 5,7-Dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, a compound of claim 54.


56. 5,6,7-Trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime, a compound of claim 54.

20

-69-

57. A pharmaceutical composition, comprising the compound of claim 54 and a pharmaceutically acceptable carrier.

58. A radiolabelled compound having the formula



(I)

or a pharmaceutically acceptable salt thereof;

wherein one of X or Y is oxygen and the other of X or Y is N—OR, where R may be hydrogen, alkyl, aryl, heteroaryl, acyl, halogen-substituted acyl or aryloyl; and

R₁ - R₄ may be hydrogen, nitro, amino, halo, haloalkyl, cyano, alkyl, alkenyl, alkynyl, azido, acylamino, alkylsulfonyl, aryl, substituted aryl, heteroaryl, alkoxy, trialkylsilyl-substituted alkoxy, aryloxy, substituted aryloxy, heteroaryloxy, a heterocyclic group, a heterocyclicoxy group, aralkoxy or haloalkoxy.

59. The radiolabelled compound of claim 58, wherein said radiolabel is ³H, ¹¹C, ¹⁴C, ¹⁵N, or ¹⁸F.

60. The radiolabelled compound of claim 58, wherein said compound is 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

61. The radiolabelled compound of claim 58, wherein said compound is 5,7-dichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

-70-

62. The radiolabelled compound of claim 58, wherein said compound is 5,6,7-trichloro-1,2,3,4-tetrahydroquinoline-2,3,4-trione-3-oxime.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/06145

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 31/47; C07D 315/22, 215/227, 215/233

US CL :514/312; 546/155;

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/312; 546/155; A61K 31/47

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS FILE, DIALOG ONE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PHARMAZIE, Volume 46, No. 19, Issued 1991 A.A. FADDA et al. "Synthesis of Certain Sulphonamides and Aminoanthraquinoline derivatives from 4 hydroxy quinoline with biological interest", pages 743-4, entire document.	1-6, 36-40, 53
Y	EP, A, 0,459,561 (BAKER et al.) 12 April 1991, see page 2, lines 1-10 and claim 1, T as CONHOH, n=0 and definitions of B.	1-6, 10, 36-40, 53
Y	US, A, 5,198,461 (WATJEN et al.) 30 March 1993, see column 1, lines 38-46.	1-6, 10, 53

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

08 AUGUST 1994

Date of mailing of the international search report

SEP 20 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DONALD G. DAUS jd

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/06145

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HELVETICA CHIMICA ACTA, VOLUME 50 Issued 1967, DAHN et al. "UBERdie 1-2-VERSCHIBUNG der SauerAmidGruppe bei der BENZIL-SAUREMLAGERUNG von CHINISATIN", pages 1911-1917, see page 1914, Structure VIII.	1-6, 10, 36-40, 53
Y	J. Chem. Soc. Volume 120, issued 1988, R. HARDMAN et al. "5 and 7 substituted 2 amino-4-hydroxy quinolines," pages 614-620. See page 615 structure.	1-6, 10, 36-40, 53
A, P	US, A, 5,252,584 (CARLING et al.) 12 October 1993, see entire document.	1-62
A, P	US, A, 5,235,956 (LIPTON) 10 August 1993, See entire document.	1-53

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/06145

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-6, 10, 35-36, 40, 53 (part of each), and 37-39
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/06145

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-6, 10, 53 (part of each), drawn to methods of using non heteroaromatic quinolines for surgical neuron loss.

Group II, claim(s) 1-9, 53 (part of each), drawn to methods of using heteroaromatic quinolines for non surgical neuron loss.

Group III, claim(s) 1-6, 10, 53 (part of each), drawn to methods of using heteroaromatic substituted quinolines for surgical neuron loss.

Group IV, claim(s) 1-9, 53 (part of each), drawn to methods of using heteroaromatic substituted quinolines for surgical neuron loss.

Group V, claim(s) 11-12, 16, 53 (part of each), 13-15, drawn to methods for neurodegenerative disease using non heteroaromatic substituted quinoline.

Group VI, claim(s) 11-12, 16, 53 (part of each), drawn to methods for neurodegenerative disease using heteroaromatic substituted quinolines.

Group VII, claim(s) 17-18, 22, 53 (part of each), 19-22, drawn to methods for treating results of excitatory amino acids using non heteroaromatic substituted quinolines.

Group VIII, claim(s) 17-18, 22, 53 (part of each), drawn to methods for treating results of excitatory amino acids using heteroaromatic substituted quinolines.

Group IX, claim(s) 23-24, 28, 41-42, 46, 53 (part of each), 25-27 and 43-45, drawn to methods for treating pain with non heteroaromatic quinolines.

Group X, claim(s) 23-24, 28, 41-42, 46, 53 (part of each), drawn to methods for treating pain with heteroaromatic substituted quinolines.

Group XI, claim(s) 29-30, 34, 53 (part of each), and 31-33, drawn to methods for treating anxiety with non heteroaromatic substituted quinolines.

Group XII, claim(s) 29-30, 34, 53 (part of each), drawn to methods for anxiety with heteroaromatic substituted quinolines.

Group XIII, claim(s) 35-36, 40, 53 (part of each), and 37-39, drawn to methods for convulsions with non heteroaromatic substituted quinolines.

Group XIV, claim(s) 35-36, 40, 53 (part of each), drawn to methods for convulsions with heteroaromatic substituted quinolines.

Group XV, claim(s) 47, 48, 52, 53 (part of each), and 49-51, drawn to methods for "psychoses" using non heteroaromatic substituted quinolines.

Group XVI, claim(s) 47, 48, 52-53 (part of each), drawn to methods for "psychoses" using heteroaromatic substituted quinolines.

Group XVII, claim(s) 54, 57 (part of each), and 55, 56, drawn to non heteroaromatic substituted quinolines.

Group XVIII, claim(s) 54, 57 (part of each), drawn to heteroaromatic substituted quinolines.

Group XIX, claim(s) 58, 59 (part of each), and 60-62, drawn to non heteroaromatic or non heterocyclic substituted radiolabelled quinolines.

Group XX, claims 58, 59 (part of each), drawn to heteroaromatic or heterocyclic substituted radiolabelled quinolines.

The terms "heteroaromatic" and "heterocyclic" cannot be completely searched in the PTO files.

PCT Rule 13.3 permits lack of unity holdings when encompassed in a single claim.

The inventions listed as Groups I-XX do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: some of compounds XVII are already known there is no "special technical feature" shown by all the inventions, because it's not "special". Note Dahn, Fadda, and Hardman.